Kancera

Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

CEO statement

“The letter of intent with Recardio Inc. makes strong business sense and improves the opportunities to advance our program in acute myocardial infarction to the next clinical phase.”

Peter Selin, CEO Kancera

Press Releases

2025-05-23
Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
2025-05-20
Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program
2025-04-08
Kancera reports Last Patient Last Visit in the KANDOVA study

Events

No upcoming events are currently in the calendar

Presentations

Presentation of Kancera’s 2025 Q1 Interim Report (in Swedish)